India reports 14,849 new COVID-19 cases, 155 more fatalities; recovery rate now 96.83%

-

New Delhi: India's COVID-19 caseload has gone up to 1,06,54,533 with 14,849 people testing positive for the coronavirus infection in a day, while the number of recoveries has surged to 1,03,16,786, according to the health ministry.

The toll due to the viral disease has climbed to 1,53,339 with 155 more fatalities, the ministry's data updated at 8 am showed.

The number of people who have recuperated from the disease has surged to 1,03,16,786, pushing the national COVID-19 recovery rate to 96.83 percent, while the case fatality rate stands at 1.44 percent.

The active COVID-19 caseload of the country remained below two lakh for the fifth consecutive day.

There are 1,84,408 active cases of the coronavirus infection in the country currently, which account for 1.73 per cent of its total caseload, the data stated.

India's COVID-19 tally had crossed the 20-lakh mark on 7 August last year, the 30-lakh mark on 23 August, the 40-lakh mark on 5 September and the 50-lakh mark on 16 September.

It went past 60 lakh on 28 September, 70 lakh on 11 October, 80 lakh on 29 October, 90 lakh on 20 November and the one-crore mark on 19 December.

According to the Indian Council of Medical Research (ICMR), a total of 19,17,66,871 samples have so far been tested in the country for the viral disease, including 7,81,752 on Saturday.

Of the 155 fresh fatalities, 56 were reported from Maharashtra, 23 from Kerala and 10 each from Delhi, Punjab and West Bengal.

Of the total 1,53,339 COVID-19 deaths reported so far in the country, Maharashtra accounts for the highest number of 50,740, followed by Tamil Nadu (12,309), Karnataka (12,193), Delhi (10,799), West Bengal (10,107), Uttar Pradesh (8,609) and Andhra Pradesh (7,147).

The ministry stressed that more than 70 per cent of the COVID-19 deaths in the country occurred due to comorbidities.

"Our figures are being reconciled with the Indian Council of Medical Research," it said on its website, adding that a state-wise distribution of the figures is subject to further verification and reconciliation.



from Firstpost India Latest News https://ift.tt/3qNoUne
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more